Annual Report

The report presents OBI Pharma's 2024 consolidated operating income of NT$62,678 thousand and a workforce of 277 employees. It identifies the Board of Directors as the highest sustainability-governance body, supported by a Sustainable Development Executive Committee, and reports approximately 10.38 metric tons of industrial waste. The report also describes continued GHG data collection, reporting in accordance with GRI Standards 2021 and SASB and TCFD criteria, while stating that external assurance procedures had not yet been executed.